Merck & Co licenses early-stage cardiovascular programme targeting aldosterone synthase
This article was originally published in Scrip
Executive Summary
Merck & Co has obtained an exclusive worldwide licence to ElexoPharm's early-stage drug development programme targeting aldosterone synthase, a cytochrome P450 enzyme involved in the generation of aldosterone. Aldosterone is known to contribute to the development of cardiovascular diseases such as hypertension.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.